Studies in Translational Regenerative Medicine
Studies in Translational Regenerative Medicine
批准号:
10178010
负责人:
ANTHONY ATALA
金额:
$19.97万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
未结题
起止时间:
2013-09-01 至 2025-06-23
中文摘要
项目总结/摘要
再生医学(RM)领域需要一种新型的研究人员,在基础RM方面训练有素
概念和方法,能够将人类生物学和工程系统与挑战意识相结合
参与推进基础研究,监管科学和临床翻译。我们T32的总体目标是
博士前培训计划,“转化再生医学研究”,仍然致力于
培养下一代经过多学科培训的研究科学家和工程师,他们将领导
新的多元化研究团队设计解决方案,以现实世界的健康问题,并推进RM
领域将最先进的多学科基础科学培训与基础设施和知识联系起来的能力
加速RM技术转化所需的基础是关键优势。到目前为止,这个T32计划已经
为10名博士生提供了成为独立RM研究人员的工具。与教师的
教育前,博士后和早期职业教师的成功记录,我们的T32计划的第一个周期
超越目标。受训人员积累了大量高质量的出版物(66份已出版/14份正在编写),
在地方、国家和国际会议上作口头和海报介绍(103次)。重要的是,100%
被任命的学员目前正在攻读博士学位或已获得博士学位。六
学员完成了T32培训和博士学位答辩,并成功进入学术或非学术领域。
学术生涯。其中,4个(66%)仍然明确专注于RM研究。招募了3名(50%),
由于他们的T32培训,进入行业职位与广泛的RM组合。WFIRM的特色
基础设施为转化研究提供设施和专业知识,从基础临床前研究
通过2期临床试验。水机构的多学科培训包括一系列活动,包括
教学课程,参与尖端团队科学,以及从事学术,
政府和工业外部。新计划强调专业和职业发展,
包括项目和时间管理,拨款写作,监管科学,GMP生产,科学
伦理该计划有3个与NIBIB一致的重点领域:1)生物材料; 2)使能技术(生物打印,
芯片上的身体、成像和多流体);以及3)应用于一种或多种应用的干细胞/细胞疗法
领域:1)心血管; 2)肌肉骨骼; 3)胃肠道/内分泌;和4)泌尿科。学员
从7个WFGS轨道中选择4个:生物医学工程,分子和细胞生物科学,神经科学或
综合生理学和药理学。经过一个共同的第一年课程(每个轨道独特),学员
从10名初级导师(19名指导教师)中确定一名,参加专业的RM课程,
毕业生委员会包括经验丰富的初级导师(10),培训导师(6),和名誉
导师(3)与职业生涯长期指导经验是一个独特的计划方面。该计划由以下人员审查:
内部和外部咨询委员会由著名的学术,政府和行业成员组成。
英文摘要
Project Summary/Abstract
The Regenerative Medicine (RM) field requires a new type of researcher, well-trained in fundamental RM
concepts and methods, able to integrate human biology and engineered systems with awareness of challenges
involved in advancing basic research, regulatory science, and clinical translation. The overall goal of our T32
pre-doctoral training program, “Studies in Translational Regenerative Medicine”, remains committed to
developing next generation multidisciplinary trained research scientists and engineers, who will lead
new diverse research teams designing solutions to real-world health problems and advance the RM
field. Ability to link state-of-the-art multidisciplinary basic science training to the infrastructure and knowledge
base required to accelerate translation of RM technologies are key strengths. To date, this T32 program has
provided 10 PhD trainees the tools to become independent RM researchers. Consistent with faculty's
successful record of educating pre-, post-doctoral and early-career faculty, the first cycle of our T32 program
exceeded goals. Trainees accrued an impressive list of quality publications (66 published/14 in process) and
oral and poster presentations (103) at local, national and international meetings. Importantly, 100% of
appointed trainees are currently working on their PhD requirements or have obtained their PhD degrees. Six
trainees completed their T32 training and PhD defense and successfully moved on to academic or non-
academic careers. Of these, 4 (66%) remain in explicitly focused RM research. Three (50%) were recruited,
because of their T32 training, into industry positions with extensive RM portfolios. WFIRM's distinctive
infrastructure provides the facilities and expertise for translational studies ranging from basic preclinical studies
through Phase 2 clinical trials. WFIRM's multidisciplinary training includes a range of activities, including
didactic courses, participation in cutting-edge team science, and new opportunities to engage in academic,
government, and industrial externships. The new program emphasizes professional and career development,
including project and time management, grant writing, regulatory science, GMP manufacturing, and scientific
ethics. The program has 3 NIBIB-aligned focus areas: 1) biomaterials; 2) enabling technologies (bioprinting,
body-on-a-chip, imaging & multifluidics); and 3) stem cells/cell therapies applied to one or more application
areas: 1) cardiovascular; 2) musculoskeletal; 3) gastrointestinal/endocrinal; and 4) urological. Trainees are
selected from 4 of 7 WFGS tracks: Biomedical Engineering, Molecular & Cellular Biosciences, Neuroscience or
Integrative Physiology and Pharmacology. After a common 1st year curriculum (unique to each track), trainees
identify one of 10 primary mentors (of 19 mentoring faculty), take specialized RM courses and choose a
graduate committee. Inclusion of seasoned Primary Mentors (10), Mentors-in-Training (6), and Emeritus
Mentors (3) with career-long mentoring experience is a unique program aspect. The program is reviewed by
Internal and External Advisory Boards composed of prominent academic, government, and industry members.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
U2C/TL1 NC KUH TRIO Program
-
批准号:10725470
-
项目类别:
-
资助金额:$48.82万
-
财政年份:2023
-
负责人:ANTHONY ATALA
-
依托单位:
Bioengineered Tissues For Uterine Reconstruction
-
批准号:10420259
-
项目类别:
-
资助金额:$58.98万
-
财政年份:2022
-
负责人:ANTHONY ATALA
-
依托单位:
Bioengineered Tissues For Uterine Reconstruction
-
批准号:10582724
-
项目类别:
-
资助金额:$49.69万
-
财政年份:2022
-
负责人:ANTHONY ATALA
-
依托单位:
Bioprinting Patterning for Cell-Laden Constructs
-
批准号:9279982
-
项目类别:
-
资助金额:$27.13万
-
财政年份:2017
-
负责人:ANTHONY ATALA
-
依托单位:
Studies in Translational Regenerative Medicine
-
批准号:10663320
-
项目类别:
-
资助金额:$16.55万
-
财政年份:2013
-
负责人:ANTHONY ATALA
-
依托单位:
Studies in Translational Regenerative Medicine
-
批准号:9133376
-
项目类别:
-
资助金额:$18.41万
-
财政年份:2013
-
负责人:ANTHONY ATALA
-
依托单位:
Studies in Translational Regenerative Medicine
-
批准号:9344634
-
项目类别:
-
资助金额:$16.03万
-
财政年份:2013
-
负责人:ANTHONY ATALA
-
依托单位:
Studies in Translational Regenerative Medicine
-
批准号:8721955
-
项目类别:
-
资助金额:$9.18万
-
财政年份:2013
-
负责人:ANTHONY ATALA
-
依托单位:
Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy
-
批准号:7630939
-
项目类别:
-
资助金额:$11.1万
-
财政年份:2008
-
负责人:ANTHONY ATALA
-
依托单位:
The Harvard Urologic Research Center
-
批准号:7500536
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:ANTHONY ATALA
-
依托单位:
Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy
-
批准号:7500809
-
项目类别:
-
资助金额:$102.51万
-
财政年份:2007
-
负责人:ANTHONY ATALA
-
依托单位:
Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy
-
批准号:7676078
-
项目类别:
-
资助金额:$102.51万
-
财政年份:2007
-
负责人:ANTHONY ATALA
-
依托单位:
Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy
-
批准号:7880311
-
项目类别:
-
资助金额:$3.88万
-
财政年份:2007
-
负责人:ANTHONY ATALA
-
依托单位:
Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy
-
批准号:7343611
-
项目类别:
-
资助金额:$105.8万
-
财政年份:2007
-
负责人:ANTHONY ATALA
-
依托单位:
PROJECT 1
-
批准号:7661996
-
项目类别:
-
资助金额:$18.85万
-
财政年份:2006
-
负责人:ANTHONY ATALA
-
依托单位:
PROJECT 1
-
批准号:7661964
-
项目类别:
-
资助金额:$19.43万
-
财政年份:2005
-
负责人:ANTHONY ATALA
-
依托单位:
MOLECULAR GENETIC ANALYSIS OF VESICOURETERAL REFLUX IN PATIENTS & THEIR FAMILIES
-
批准号:6568548
-
项目类别:
-
资助金额:$2.88万
-
财政年份:2001
-
负责人:ANTHONY ATALA
-
依托单位:
MOLECULAR GENETIC ANALYSIS OF VESICOURETERAL REFLUX IN PATIENTS & THEIR FAMILIES
-
批准号:6485554
-
项目类别:
-
资助金额:$2.88万
-
财政年份:2000
-
负责人:ANTHONY ATALA
-
依托单位:
MOLECULAR GENETIC ANALYSIS OF VESICOURETERAL REFLUX IN PATIENTS & THEIR FAMILIES
-
批准号:6441955
-
项目类别:
-
资助金额:$2.88万
-
财政年份:2000
-
负责人:ANTHONY ATALA
-
依托单位:
BIOENGINEERING OF BLADDER TISSUES
-
批准号:6643565
-
项目类别:
-
资助金额:$7.44万
-
财政年份:1999
-
负责人:ANTHONY ATALA
-
依托单位:
海外基金